“Know Hepatitis B:” A Multilingual Communications Campaign Promoting Testing           for Hepatitis B Among Asian Americans and Pacific Islanders

Jorgensen, Cynthia M.; Chen, Sherry; Carnes, C. Amanda; Block, Joan M.; Chen, Daniel; Caballero, Jeffrey; Moraras, Kate; Cohen, Chari

doi:10.1177/00333549161310s206

Cited by 11 publications

(13 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other recommended interventions to promote uptake of hepatitis testing and linkage to care include peer and lay health worker support in community-based settings, clinician reminders to offer testing, and testing as part of integrated services, alongside the use of different media strategies to promote awareness about hepatitis in the general population [ 6 , 15 , 59 , 60 ].…”

Section: Technological Advances and Innovations To Improve Access To mentioning

confidence: 99%

The future of viral hepatitis testing: innovations in testing technologies and approaches

et al. 2017

View full text Add to dashboard Cite

A large burden of undiagnosed hepatitis virus cases remains globally. Despite the 257 million people living with chronic hepatitis B virus infection, and 71 million with chronic viraemic HCV infection, most people with hepatitis remain unaware of their infection. Advances in rapid detection technology have created new opportunities for enhancing access to testing and care, as well as monitoring of treatment. This article examines a range of other technological innovations that can be leveraged to provide more affordable and simplified approaches to testing for HBV and HCV infection and monitoring of treatment response. These include improved access to testing through alternative sampling methods (use of dried blood spots, oral fluids, self-testing) and combination rapid diagnostic tests for detection of HIV, HBV and HCV infection; more affordable options for confirmation of virological infection (HBV DNA and HCV RNA) such as point-of-care molecular assays, HCV core antigen and multi-disease polyvalent molecular platforms that make use of existing centralised laboratory based or decentralised TB and HIV instrumentation for viral hepatitis testing; and finally health system improvements such as integration of laboratory services for procurement and sample transportation and enhanced data connectivity to support quality assurance and supply chain management.

show abstract

Section: Technological Advances and Innovations To Improve Access To mentioning

confidence: 99%

The future of viral hepatitis testing: innovations in testing technologies and approaches

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The majority of people with CHB live in countries that now have national viral hepatitis plans [11]. Many of these plans encompass population-specific communications campaigns to improve awareness and promote testing [12]; community-based programs to provide testing and linkage to care to under-served and high-risk communities [13][14][15]; and pilot projects integrating HBV testing and care into health systems to improve the capacity of primary care providers to test and manage people with CHB [15][16][17][18][19].…”

Section: Introductionmentioning

confidence: 99%

The Lived Experience of Chronic Hepatitis B: A Broader View of Its Impacts and Why We Need a Cure

Block

Wang

et al. 2020

Viruses

Self Cite

View full text Add to dashboard Cite

Chronic hepatitis B (CHB) is one of the most widespread liver diseases in the world. It is currently incurable and can lead to liver cirrhosis and cancer. The considerable impacts on society caused by CHB through patient mortality, morbidity, and economic loss are well-recognised in the field. This is, however, a narrow view of the harms, given that people living with CHB can be asymptomatic for the majority of their life-long infection. Of less-appreciated importance are the psychosocial harms, which can continue throughout an affected person’s lifetime. Here we review the broad range of these impacts, which include fear and anxiety; financial loss and instability; stigma and discrimination; and rejection by society. Importantly, these directly affect patient diagnosis, management, and treatment. Further, we highlight the roles that the research community can play in taking these factors into account and mitigating them. In particular, the development of a cure for hepatitis B virus infection would alleviate many of the psychosocial impacts of CHB. We conclude that there should be a greater recognition of the full impacts associated with CHB to bring meaningful, effective, and deliverable results to the global community living with hepatitis B.

show abstract

“…There have been several strategies identified that lead to increased testing and linkage to care for persons with HBV that may be applied to address gaps for pregnant women with HBV infection identified in this study. Patient education has shown success by facilitating increased HBV testing in hard to reach populations [ 15 , 17 , 18 ] and can be applied to pregnant women. In addition, provider education is important to ensure HBV testing is performed and correctly interpreted, and persons with positive results receive appropriate management [ 19 ], which can be applied to prenatal care clinics.…”

Section: Discussionmentioning

confidence: 99%

Hepatitis B Virus Testing and Care among Pregnant Women Using Commercial Claims Data, United States, 2011–2014

Harris

Isenhour

Schillie

et al. 2018

Infectious Diseases in Obstetrics and Gynecology

View full text Add to dashboard Cite

Introduction Pregnant women should receive hepatitis B virus (HBV) testing with hepatitis B surface antigen (HBsAg), but it is unclear whether HBV-infected pregnant women are linked to care. Methods We analyzed MarketScan™ commercial insurance claims. We included pregnant women, aged 10–50 years, with 42 weeks of continuous enrollment before (predelivery) and 6 months after (postdelivery) the first delivery claim for each unique pregnancy between 1/1/2011 and 6/30/2014. We identified claims for HBsAg testing by CPT code and described the care continuum among pregnancies with an associated ICD-9 HBV diagnosis code by demographic and clinical characteristics, including HBV-directed care ([HBV DNA or hepatitis B e antigen] and ALT test codes) and antiviral treatment (claims for tenofovir, entecavir, lamivudine, adefovir, or telbivudine) pre- and postdelivery. Results There were 870,888 unique pregnancies (819,752 women) included. Before delivery, 714,830 (82%) pregnancies had HBsAg test claims, but this proportion decreased with subsequent pregnancies (p < 0.0001): second (80%), third (71%), and fourth (61%). We identified 1,190 (0.14%) pregnancies with an associated HBV diagnosis code: most were among women aged ≥ 30 years (76%) residing in the Pacific (34%) or Middle Atlantic (18%) regions. Forty-two percent of pregnancies with an HBV diagnosis received HBV-directed care (42% predelivery and 39% postdelivery). Antiviral treatment was initiated before delivery in 128 (13%) of 975 pregnancies and postdelivery in 16 (1.6%) pregnancies. Conclusions While most of these commercially insured pregnant women received predelivery HBV screening, we identified gaps in HBV testing and the HBV care continuum which highlight potential targets for public health interventions.

show abstract

“Know Hepatitis B:” A Multilingual Communications Campaign Promoting Testing for Hepatitis B Among Asian Americans and Pacific Islanders

Cited by 11 publications

References 8 publications

The future of viral hepatitis testing: innovations in testing technologies and approaches

The future of viral hepatitis testing: innovations in testing technologies and approaches

The Lived Experience of Chronic Hepatitis B: A Broader View of Its Impacts and Why We Need a Cure

Hepatitis B Virus Testing and Care among Pregnant Women Using Commercial Claims Data, United States, 2011–2014

Contact Info

Product

Resources

About